Skip to main content may receive compensation from affiliate partners for some links on the site. Read our full Disclosure here.

European Countries Suspend the Oxford/AstraZeneca COVID-19 Vaccine After Reports of Serious Blood Clots


The COVID-19 vaccine rollout in Europe hit a major roadblock when several countries halted the use of the Oxford/AstraZeneca jab.

After reports of serious blood clots, countries have either suspended use of suspect batches or the vaccine altogether.

Despite examples of recipients with no prior health conditions dying shortly after the vaccine, medical watchdogs insist the benefits outweigh the risks.

You would think death is a pretty serious risk for taking a vaccine for a virus with well over a 99% survival rate.

But governments and medical overlords around the world want to keep using us as their guinea pigs.

And many people line up for their jab without doing any prior research.

But with the temporary suspension of the Oxford/AstraZeneca vaccine, maybe more people will do some investigating into the real risks of the jab.

Here’s the latest fallout:

CNBC reported:

Denmark, Norway and Iceland announced Thursday they will temporarily suspend the use of the coronavirus vaccine developed by AstraZeneca and the University of Oxford.

The Danish Health Authority said it would temporarily stop using the shot in its vaccination program as a precaution “after reports of severe cases of blood clots in people who have been vaccinated with the COVID-19 vaccine from AstraZeneca.”

“Against this background, the European Medicines Agency has launched an investigation into the AstraZeneca vaccine. One report relates to a death in Denmark. At present, it cannot be concluded whether there is a link between the vaccine and the blood clots,” the health authority said in a statement.

It did not specify how many reports of blood clots there had been, or where they had originated.

Later on Thursday, both Iceland and Norway made similar announcements.

Local media reported that Thailand also delayed its rollout as well as plans to inoculate Prime Minister Prayuth Chan-ocha and his cabinet with the AstraZeneca vaccine. The prime minister was slated to be the country’s first recipient and had been scheduled to be vaccinated Friday morning, according to local media.

The announcements come after a similar move in Austria at the start of the week, where authorities are investigating the death of one person and the illness of another after they received doses of the vaccine.

Shares of AstraZeneca on the London market slipped 2.5% on Thursday. The University of Oxford would not comment on the announcement when contacted by CNBC.

A spokesperson for AstraZeneca said the company was aware of the statement made by the Danish Health Authority that it’s currently investigating potential adverse effects related to the vaccine.

“Patient safety is the highest priority for AstraZeneca. Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine, and that includes COVID-19 Vaccine AstraZeneca. The safety of the vaccine has been extensively studied in Phase III clinical trials and Peer-reviewed data confirms the vaccine is generally well tolerated,” AstraZeneca said in a statement to CNBC.

Soren Brostrom, director of the National Board of Health in Denmark, insisted that the 14-day suspension was a precaution while investigations took place.

“It is important to emphasize that we have not opted out of the AstraZeneca vaccine, but that we are putting it on hold. There is good evidence that the vaccine is both safe and effective. But both we and the Danish Medicines Agency have to react to reports of possible serious side effects, both from Denmark and other European countries,” he said.

Stop Big Tech From Tracking You Online: PureVPN

Life Site News added these details:

Austria, Estonia, Lativa, Lithuania, and Luxembourg have all suspended the use of a suspect batch of the Oxford/AstraZenica vaccine. The batch, which consists of 1 million doses and is called ABV5300, was originally sent to 17 European countries. It has been implicated in the death of a 49-year-old nurse in Zwettl, Austria. A 35-year-old woman in the same town survived a pulmonary embolism she suffered shortly after taking a dose from the same batch.

Italy has suspended the use of a different batch of the Oxford/AstraZenica vaccine, ABV 2856, after 43-year-old naval officer Stefano Paternò had a fatal heart attack 24 hours after receiving a dose of it this week in Sicily. According to the Corriere della Sera, Paternò was in good health before his inoculation, and then afterward suffered a fever, followed by convulsions. There are also reports that a second Italian, a 50-year-old policeman named Davide Villa, also died after receiving the vaccine in Sicily. Villa developed deep vein thrombosis after his inoculation and succumbed 12 days later.

Denmark, Iceland, and Norway have suspended using any batch of the Oxford/AstraZenica vaccine after the death of a Danish woman with blood clots. The 60-year-old woman died shortly after receiving the vaccine.

According to the Financial Times, residents of Denmark who have been inoculated with the Oxford/AstraZenica vaccine in the past two weeks will be contacted by health authorities. They will be instructed in the signs of blood clots and encouraged to “contact their doctors if they suffer any new or surprising symptoms.”

According to the BBC, the medical regulator for the European Union has stated that there is no proof that the Oxford/AstraZenica vaccine causes blood clots and that its benefits still “outweigh its risks.”


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

We Love Trump
Thanks for sharing!
Send this to a friend